文献速递胸部肿瘤放疗放疗物理与技术

免疫细胞有效剂量(EDIC)对局限期小细胞肺癌淋巴细胞最低值与生存的影响

Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC.
PubMed 文献 · Radiother Oncol · 2021-06-15

本研究纳入2012至2017年单中心接受根治性放化疗的503例局限期小细胞肺癌(LS-SCLC)患者,评估免疫细胞有效剂量(EDIC)与淋巴细胞最低值、总生存(OS)及无进展生存(PFS)的相关性。结果显示EDIC与淋巴细胞最低值显著相关,且为PFS和OS的独立预测因素,提示EDIC可作为LS-SCLC的生存替代标志物。

要点

  • EDIC与放疗期间淋巴细胞最低值显著相关(单因素及多因素线性回归p<0.001)。
  • EDIC(HR=0.1072,p=0.005)和淋巴细胞最低值(HR=0.345,p=0.003)均为OS的独立预测因素。
  • EDIC对PFS亦显著(HR=1.046,p=0.026),联合EDIC模型OS预测C-index达0.684。

核心结论

  • EDIC是LS-SCLC患者淋巴细胞最低值、PFS和OS的独立预测因素,可作为淋巴细胞最低值的预测指标及OS的替代标志物。

研究设计与样本

  • 单中心回顾性研究,纳入2012至2017年接受根治性放化疗的503例局限期小细胞肺癌患者,所有患者放疗前、中、后均有包括淋巴细胞计数的完整血常规检测。

主要发现

  • 503例可评估患者平均EDIC为7.34 Gy,放疗期间平均淋巴细胞最低值为0.48×10^9 cells/L,显著低于放疗前的1.65×10^9 cells/L(p<0.001)。
  • EDIC与淋巴细胞最低值在单因素(p<0.001)和多因素线性回归(p<0.001)中均显著相关。
  • 多因素分析显示EDIC(HR=0.1072,p=0.005)和淋巴细胞最低值(HR=0.345,p=0.003)对OS均显著,EDIC对PFS亦显著(HR=1.046,p=0.026)。
  • OS预测C-index分别为:单纯淋巴细胞最低值0.593、单纯EDIC 0.617、联合淋巴细胞最低值模型0.676、联合EDIC模型0.684。

临床怎么用

  • 在LS-SCLC根治性放化疗中应关注EDIC,以减轻淋巴细胞毒性并改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective dose to immune cell (EDIC), an estimated radiation dose to the circulating lymphocytes, is of significance for overall survival (OS) in non-small cell lung cancer. This study aimed to validate the EDIC's OS effect on limited-stage small cell lung cancer (LS-SCLC). METHOD AND MATERIALS: This study included LS-SCLC patients received definitive chemo-radiation in one single center from 2012 to 2017. All patients had multiple complete-blood-count tests including lymphocyte count at pre-, during- and end- radiotherapy. EDIC, computed according to doses of the lung, heart, and the total body, was assessed for its correlation with lymphocyte nadir, OS and progression free survival (PFS). RESULTS: Of 503 eligible patients, the mean EDIC was 7.34 Gy. The mean lymphocyte nadir was 0.48 × 109 cells/L, significantly lower than 1.65 × 109 cells/L at pre-radiotherapy (p < 0.001). EDIC was significantly correlated with lymphocyte nadir under both univariate (p < 0.001) and multivariable linear regression (p < 0.001). Multivariable analysis showed EDIC (HR = 0.1072, p = 0.005) and lymphocyte nadir (HR = 0.345, p = 0.003) were both significant for OS. EDIC was also significant for PFS (HR = 1.046, p = 0.026). The C-indexes of OS prediction were 0.593, 0.617, 0.676, and 0.684, for lymphocyte nadir alone, EDIC alone, combined lymphocyte nadir model, and combined EDIC model, respectively. CONCLUSIONS: This study demonstrated that EDIC is an independent predictor for lymphocyte nadir, PFS and OS. EDIC may serve as a predictor for lymphocyte nadir and a surrogate marker for OS in LS-SCLC. More attention should be paid to EDIC to decease the lymphocyte toxicity and improve survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yu Y, Fu P, Jin JY, et al. Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. Radiother Oncol. 2021. PMID: 34139210. doi:10.1016/j.radonc.2021.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。